Pfizer
Open
$26.18
Prev. Close
$26.19
High
$26.21
Low
$26.11
Market Snapshot
$149.04B
19.9
1.42
$63.63B
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
Recently from Cashu
Pfizer Expands HYMPAVZI Approval, Enhancing Hemophilia Treatment Options in Europe
Pfizer Inc (Ticker: PFE) has made significant strides in the treatment of hemophilia with the recent expansion of the approval of its drug, HYMPAVZI (marstacimab), by the European Commission. This exp…
Pfizer Pursues Lyme Disease Vaccine Amid Clinical Trials and Regulatory Challenges
Pfizer Advances Lyme Disease Vaccine Despite Clinical Trial Challenges Pfizer is pushing ahead with its regulatory application for a Lyme disease vaccine candidate, even in the wake of a recent Phase…
CNBC Cures: A Campaign Raising Awareness for Rare Diseases and Patient Experiences
CNBC Cures: Raising Awareness for Rare Diseases In a significant effort to illuminate the struggles of Americans living with rare diseases, CNBC has initiated "CNBC Cures," a campaign dedicated to amp…
Pfizer's TALAPRO-3 Study Promises Advances in Prostate Cancer Treatment with Talzenna and Xtandi
Pfizer's Promising Advance in Prostate Cancer Treatment: TALAPRO-3 Study Results Pfizer announces important topline results from the Phase 3 TALAPRO-3 study, focusing on the combination of Talzenna (t…